Amphastar Pharmaceuticals (AMPH) closed out FY 2025 with fourth quarter revenue of US$183.1 million and basic EPS of US$0.53, compared with prior year Q4 revenue of US$186.5 million and EPS of US$0.79, as trailing net profit margin moved from 21.8% to 13.6% over the last 12 months. Over the past six reported quarters, revenue has remained within a relatively narrow range of roughly US$170 million to US$192 million per quarter, while EPS has ranged from US$0.37 to US$0.83, giving investors a clearer view of how earnings track against a relatively steady top line. With trailing EPS of US$2.10 on US$719.9 million of revenue and a current share price of US$24.03, the latest report places greater attention on how much of the recent margin compression investors are prepared to look through.

See our full analysis for Amphastar Pharmaceuticals.

With the headline figures on the table, the next step is to see how these results align with the dominant narratives around Amphastar, from growth potential to margin risk, and how the new data may prompt those stories to adjust.

Margin Compression Stands Out Against Stable Sales

• Over the last 12 months, Amphastar generated US$719.9 million of revenue with net income of US$98.1 million, which works out to a 13.6% net margin compared with 21.8% a year earlier, while quarterly revenue stayed in a tight band of roughly US$170 million to US$192 million.
• Consensus narrative points to pressure on key products like glucagon and epinephrine, and the margin shift lines up with that concern, but it also sits alongside capacity expansion and pipeline spend that are meant to support future earnings.
  • R&D and capital spending are described as higher year on year, yet trailing earnings are still classified as high quality, so the lower 13.6% margin is coming from real operating pressure rather than one off noise.
  • At the same time, the portfolio remains concentrated in a few products and competition is expected to stay intense, which fits with the idea that recent margin compression could persist if pricing pressure on those core products continues.

Valuation Gap Versus 10.9x P/E

• At a share price of US$24.03 and trailing EPS of US$2.10, Amphastar trades on a P/E of about 10.9x, compared with 16.7x for the US Pharmaceuticals industry, a 52.3x peer average and a DCF fair value of roughly US$80.42 in the analysis.
• Bulls argue that capacity expansion, BAQSIMI growth and new products like AMP 002 and AMP 007 could justify a higher multiple over time, but the current numbers create a clear tension between that view and the recent margin and growth profile.
  • Five year earnings growth averaged 28.3% per year, yet forward earnings are forecast at only 2.6% per year and revenue at 4.5% per year, both below broader US market forecasts, which works against the stronger growth story bulls focus on.
  • The roughly 70% gap between the current price and the DCF fair value in the data supports a value angle for bulls, while the softer 13.6% net margin and modest growth forecasts help explain why the market is not pricing Amphastar closer to that estimate today.

Have a closer look at why some investors lean optimistic despite the compressed margins and modest growth forecasts by reading the full bullish narrative for Amphastar. 🐂 Amphastar Pharmaceuticals Bull Case

Bear Concerns Around Debt And Slower Growth

• Bears highlight two main pressure points in the recent data set, a high level of debt and the reduction in net margin from 21.8% to 13.6% over the last year, alongside forward earnings growth expectations of 2.6% per year and revenue growth of 4.5% per year, both below broader US market estimates.
• Skeptics argue that heavier competition in glucagon and epinephrine, plus higher R&D and compliance costs, could keep margins under strain, and the latest numbers give that cautious view some support while also showing where it might be too harsh.
  • Trailing twelve month net income of US$98.1 million on US$719.9 million of revenue shows the company is still clearly profitable, which challenges the idea that competition has already driven earnings to a weak base.
  • However, the lower growth forecasts and the note about high debt mean bears can point to both financial leverage and softer expected growth as reasons the stock might continue to trade at a discount to industry and peer P/E multiples.

See how the more cautious investors frame these same figures and what they think could go wrong in the detailed bear case. 🐻 Amphastar Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Amphastar Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the data so far? If you want your own take, move quickly to review the key risks and upsides in the 2 key rewards and 2 important warning signs

See What Else Is Out There

Amphastar is working through compressed net margins, softer growth forecasts and a high debt load, which together help explain its discounted P/E versus peers.

If that mix of margin pressure and leverage has you cautious, compare it with companies that pair earnings power with stronger finances using our solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.